EXEL
EXELIXIS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 18 to Feb 24 ▼ 3 days of insider sells: $7.8M by 2 insiders, avg $44.20
- Feb 28 ▲ Three major passive institutional investors, Morgan Stanley, Wells F…
- May 7 ▼ 3 insiders sell $4.1M at $46.02
- May 18 to Jun 1 ▼ 4 days of insider sells: $6.6M by 6 insiders, avg $50.11
- Jun 25 ▼ Truist Securities downgrades
- Aug 10 ▼ 1 insider sell $526.5K at $53.66
- Aug 19 BMO Capital initiates
- Sep 11 ▼ Exelixis disclosed that the FDA extended the review period for its N…
- Sep 16 Trial readout: T-90d Trial Readout: XL092 (Phase 3)
- Sep 21 Trial readout: T-90d Trial Readout: XL092 (Phase 3)
- Sep 28 Trial readout: T-90d Trial Readout: XL092 (Phase 3)
- Oct 29 ▲ Earnings: EXEL Q3 2026 Earnings: EPS $0.94 (+15.6% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
9 insiders sold $19.0M.
- InstitutionsMIXED
Q2 2026: 45 added (2 new), 46 trimmed or exited. Largest new: Bank Of Nova Scotia $22.8M, Ing Groep Nv $16.9M.
- AnalystsBULLISH
11 of 24 rate it Buy or better. Median target $60.00 (−11%).
- Short sellersSTEADY
Short interest −6.3% to 25.59M shares. 11.7 days to cover, ≈10.5% of shares.
- TrendUPTREND
8% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 8.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| D. E. Shaw & Co., Inc. | ADD | $302.1M |
| UBS Group AG | ADD | $172.4M |
| GOLDMAN SACHS GROUP INC | ADD | $146.4M |
| BANK OF AMERICA CORP /DE/ | ADD | $116.9M |
| AMERICAN CENTURY COMPANIES INC | ADD | $97.5M |
| JANE STREET GROUP, LLC | ADD | $76.3M |
| JPMORGAN CHASE & CO | ADD | $71.1M |
| MILLENNIUM MANAGEMENT LLC | ADD | $66.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
24 analystsPrice is inside the target range. Median implies −11%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 5, 2026 | Leerink Partners MAINTAIN | Market Perform |
| Nov 2, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 30, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 30, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Oct 30, 2026 | RBC Capital MAINTAIN | Sector Perform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Beckerle Mary C Director Aug 10, 2026 | SELL | $526.5K |
WYSZOMIERSKI JACK L Director Jun 1, 2026 | SELL | $198.4K |
Eckhardt Sue Gail Director Jun 1, 2026 | SELL | $492.0K |
JOHNSON DAVID EDWARD Director May 27, 2026 | AWARD | 19,133 sh |
Freire Maria C Director May 27, 2026 | AWARD | 8,367 sh |
POSTE GEORGE Director May 27, 2026 | AWARD | 8,367 sh |
WYSZOMIERSKI JACK L Director May 27, 2026 | AWARD | 8,367 sh |
Oliver Bob Director May 27, 2026 | AWARD | 8,367 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 1 bullish · 2 bearish · 13 neutral- NEUTRAL SC 13GNov 9, 2026
Farallon Capital Management disclosed a new 5%+ passive stake in Exelixis, reporting beneficial…
Farallon's new passive stake signals conviction in Exelixis following strong Q3 results and maintained guidance. Monitor for any future 13D conversion or additional accumulation, though the filing…
- BEARISH SC 13D/ANov 9, 2026
Farallon Capital Management filed Amendment No. 9 to its Schedule 13D on Exelixis, reporting that…
Farallon's exit below the 5% threshold removes a known activist overhang and suggests the campaign has de-escalated. Monitor for any remaining selling by Farallon in the coming weeks and watch for…
- NEUTRAL 8-KOct 29, 2026
Exelixis reported Q3 2026 total revenues of $658.7M (up 10.2% YoY) and GAAP diluted EPS of $0.85…
The EPS miss versus consensus is notable but offset by a revenue beat and maintained guidance. The zanzalintinib PDUFA delay to March 2027 removes near-term catalyst but the Azurity settlement and…
- NEUTRAL INST-CLUSTEROct 20, 2026
Four small asset managers accumulated $5.8M in new EXEL positions during Q3 2026, while one larger…
The cluster is too small in scale and conviction to justify a directional read. The single seller's $15.6M trim dominates the signal. Monitor next 13F for whether Assenagon's continued selling…
All EXEL filing & press-release reports (16)
- SC 13G reportNov 9, 2026
- SC 13D/A reportNov 9, 2026
- 8-K reportOct 29, 2026
- INST-CLUSTER reportOct 20, 2026
- INST-CLUSTER reportOct 12, 2026
- 8-K reportSep 11, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportMay 28, 2026
- CLUSTER reportMay 28, 2026
- 8-K reportMay 29, 2026
- CLUSTER reportMay 28, 2026
- CLUSTER reportMay 22, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMay 7, 2026
- DEFA14A reportApr 17, 2026
- INST-CLUSTER reportFeb 28, 2026